ProCite
RefWorks
Reference Manager
BibTeX
Zotero
EndNote
-
1.
World Health Organization, 2015. Chagas disease in Latin America: an epidemiological update based on 2010 estimates. Wkly Epidemiol Rec 6: 33–44.
-
2.
World Health Organization, 2012. Research priorities for Chagas disease, human African trypanosomiasis and leishmaniasis. World Health Organ Tech Rep Ser 975: 1–100.
-
3.
Sguassero Y, Cuesta CB, Roberts KN, Hicks E, Comandé D, Ciapponi A, Sosa-Estani S, 2015. Course of chronic Trypanosoma cruzi infection after treatment based on parasitological and serological tests: a systematic review of follow-up studies. PLoS One 10: e0139363.
-
4.
Pinazo MJ et al. 2014. Biological markers for evaluating therapeutic efficacy in Chagas disease, a systematic review. Expert Rev Anti Infect Ther 12: 479–496.
-
5.
Albareda M et al. 2018. Distinct treatment outcomes of antiparasitic therapy in Trypanosoma cruzi-infected children is associated with early changes in cytokines, chemokines, and T-cell phenotypes. Front Immunol 9: 1–15.
-
6.
Santamaría AL, De Rissio AM, Riarte A, Garavaglia PA, Bruballa AC, Rodríguez MA, Irazu LE, Ruiz AM, García GA, 2013. Use of an enzyme-linked immunosorbent assay that utilizes the Tc13Tul antigen of Trypanosoma cruzi to monitor patients after treatment with benznidazole. Diagn Microbiol Infect Dis 76: 197–205.
-
7.
Zrein M et al. 2018. A novel antibody surrogate biomarker to monitor parasite persistence in Trypanosoma cruzi-infected patients. PLoS Negl Trop Dis 12: 1–16.
-
8.
Granjon E, Dichtel-Danjoy ML, Saba E, Sabino E, Campos de Oliveira L, Zrein M, 2016. Development of a novel multiplex immunoassay multi-cruzi for the serological confirmation of Chagas disease. PLoS Negl Trop Dis 10: 1–15.
-
9.
Viotti R et al. 2011. Impact of aetiological treatment on conventional and multiplex serology in chronic Chagas disease. PLoS Negl Trop Dis 5: e1314.
-
10.
Balouz V, Melli LJ, Volcovich R, Moscatelli G, Moroni S, Ballering G, Bisio M, Buscaglia CA, Altcheh J, 2017. The trypomastigote small surface antigen from Trypanosoma cruzi improves treatment evaluation and diagnosis in pediatric Chagas disease. J Clin Microbiol 55: 3444–3453.
-
11.
Tekiel V, Alba-Soto CD, González Cappa SM, Postan M, Sánchez DO, 2009. Identification of novel vaccine candidates for Chagas’ disease by immunization with sequential fractions of a trypomastigote cDNA expression library. Vaccine 27: 1323–1332.
-
12.
García EA, Ziliani M, Agüero F, Bernabó G, Sánchez DO, Tekiel V, 2010. TcTASV: a novel protein family in Trypanosoma cruzi identified from a subtractive trypomastigote cDNA library. PLoS Negl Trop Dis 4: 6.
-
13.
Bernabó G, Levy G, Ziliani M, Caeiro LD, Sánchez DO, Tekiel V, 2013. TcTASV-C, a protein family in Trypanosoma cruzi that is predominantly trypomastigote-stage specific and secreted to the medium. PLoS One 8: 1–10.
-
14.
Caeiro LD, Alba-Soto CD, Rizzi M, Solana ME, Rodriguez G, Chidichimo AM, Rodriguez ME, Sánchez DO, Levy GV, Tekiel V, 2018. The protein family TcTASV-C is a novel Trypanosoma cruzi virulence factor secreted in extracellular vesicles by trypomastigotes and highly expressed in bloodstream forms. PLoS Negl Trop Dis 12: 1–26.
-
15.
Floridia-Yapur N et al. 2016. The TcTASV proteins are novel promising antigens to detect active Trypanosoma cruzi infection in dogs. Parasitology 143: 1382–1389.
-
16.
Camussone C, Gonzalez V, Belluzo MS, Pujato N, Ribone ME, Lagier CM, Marcipar IS, 2009. Comparison of recombinant Trypanosoma cruzi peptide mixtures versus multiepitope chimeric proteins as sensitizing antigens for immunodiagnosis. Clin Vaccine Immunol 16: 899–905.
-
17.
Monje-Rumi M et al. 2013. Benznidazole treatment in chronic children infected with Trypanosoma cruzi: serological and molecular follow-up of patients and identification of discrete typing units. Acta Trop 128: 130–136.
-
18.
Sosa-Estani S, Segura EL, Ruiz AM, Velazquez E, Porcel BM, Yampotis C, 1998. Efficacy of chemotherapy with benznidazole in children in the indeterminate phase of Chagas’ disease. Am J Trop Med Hyg 59: 526–529.
-
19.
Escribà JM, Ponce E, Romero AdeD, Viñas PA, Marchiol A, Bassets G, Palma PP, Lima MA, Zúniga C, Ponce C, 2009. Treatment and seroconversion in a cohort of children suffering from recent chronic Chagas infection in Yoro, Honduras. Mem Inst Oswaldo Cruz 104: 986–991.
-
20.
Sánchez Negrette O, Sánchez Valdéz FJ, Lacunza CD, García Bustos MF, Mora MC, Uncos AD, Basombrío MA, 2008. Serological evaluation of specific-antibody levels in patients treated for chronic Chagas’ disease. Clin Vaccine Immunol 15: 297–302.
| Past two years | Past Year | Past 30 Days | |
|---|---|---|---|
| Abstract Views | 4 | 4 | 4 |
| Full Text Views | 573 | 267 | 4 |
| PDF Downloads | 126 | 61 | 4 |
TcTASV Antigens of Trypanosoma cruzi: Utility for Diagnosis and High Accuracy as Biomarkers of Treatment Efficacy in Pediatric Patients
The discovery and characterization of novel parasite antigens to improve the diagnosis of Trypanosoma cruzi by serological methods and for accurate and rapid follow-up of treatment efficiency are still needed. TcTASV is a T. cruzi–specific multigene family, whose products are expressed on the parasite stages present in the vertebrate host. In a previous work, a mix of antigens from subfamilies TcTASV-A and TcTASV-C (Mix A + C) was sensitive and specific to identify dogs with active infection of high epidemiological relevance. Here, TcTASV-A and TcTASV-C were assayed separately as well as together (Mix A + C) in an ELISA format on human samples. The Mix A + C presented moderate sensitivity (78%) but high diagnostic accuracy with a 100% of specificity, evaluated on healthy, leishmaniasic, and Strongyloides stercoralis infected patients. Moreover, antibody levels of pediatric patients showed—2 years posttreatment—diminished reactivity against the Mix A + C (P < 0.0001), pointing TcTASV antigens as promising tools for treatment follow-up.
Author Notes
Authors’ addresses: Noelia Floridia-Yapur, Cátedra de Química Biológica, Facultad de Ciencias Naturales, Universidad Nacional de Salta, Salta, Argentina, and Instituto de Investigaciones de Enfermedades Tropicales (IIET), Sede Regional Orán, Universidad Nacional de Salta, Orán-Salta, Argentina, E-mail: narfy89@gmail.com. Mercedes Monje-Rumi, Paula Ragone, Juan J. Lauthier, Nicolás Tomasini, Anahí Alberti D’Amato, Patricio Diosque, Instituto de Patología Experimental (IPE-CONICET), Facultad de Ciencias de la Salud, Universidad Nacional de Salta, Salta, Argentina, E-mails: mariamercedes.mr@gmail.com, p_ragone@yahoo.com.ar, juanjoselauthier@gmail.com, biol.nicolas.tomasini@gmail.com, anahimaiten@gmail.com, and patricio.diosque@gmail.com. Rubén R. Cimino, Instituto de Investigaciones de Enfermedades Tropicales (IIET), Sede Regional Orán, Universidad Nacional de Salta, Orán-Salta, Argentina, E-mail: rubencimino@gmail.com. José F. Gil, Instituto de Investigaciones en Energía No Convencional (INENCO-CONICET), CCT-Salta, Salta, Argentina, E-mail: jgil.unsa@gmail.com. Daniel O. Sanchez and Valeria Tekiel, Instituto de Investigaciones Biotecnológicas “Dr. Rodolfo A. Ugalde” (IIBIO), Universidad Nacional de San Martín, UNSAM-CONICET, Buenos Aires, Argentina, E-mails: dsanchez21@gmail.com and valet@iib.unsam.edu.ar. Julio R. Nasser, Cátedra de Química Biológica, Facultad de Ciencias Naturales, Universidad Nacional de Salta, Salta, Argentina, E-mail: jrnasser@hotmail.com.